Show simple item record

dc.contributor.authorHall, Charlotte L.
dc.contributor.authorGroom, Madeleine J.
dc.contributor.authorKochhar, Puja
dc.contributor.authorRoberts, Samantha
dc.contributor.authorSayal, Kapil
dc.contributor.authorXia, Jun
dc.contributor.authorHollis, Chris P.
dc.contributor.authorLiddle, Elizabeth B.
dc.date.accessioned2019-10-09T10:04:05Z
dc.date.available2019-10-09T10:04:05Z
dc.date.issued2019
dc.identifier.citationKrinzinger, H., Hall, C. L., Groom, M. J., T Ansari, M., Banaschewski, T., Buitelaar, J. K., Carucci, S., Coghill, D., Danckaerts, M., Dittmann, R. W., et al. (2019). Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence [In Press]. Neuroscience and Biobehavioral Reviews, DOI: 10.1016/j.neubiorev.2019.09.023.en
dc.identifier.other10.1016/j.neubiorev.2019.09.023
dc.identifier.urihttps://repository.nottinghamshirehealthcare.nhs.uk/handle/123456789/3333
dc.descriptionArticle in pressen
dc.descriptionArticle as accepted for publication in Neuroscience and Biobehavioral Reviews published by Elsevier available at https://dx.doi.org/10.1016/j.neubiorev.2019.09.023
dc.description© 2019. This manuscript is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.description.abstractMethylphenidate (MPH), the most common medication for children with Attention Deficit/Hyperactivity Disorder (ADHD) in many countries, is often prescribed for long periods of time. Any long-term psychotropic treatment in childhood raises concerns about possible adverse neurological and psychiatric outcomes. We aimed to map current evidence regarding neurological and psychiatric outcomes, adverse or beneficial, of long-term MPH (> 1 year) treatment in ADHD. We coded studies using a "traffic light" system: Green: safe/favours MPH; Amber: warrants caution; Red: not safe/not well-tolerated. Un-categorisable study findings were coded as "Unclear". Although some evidence suggests an elevated risk of psychosis and tics, case reports describe remission on discontinuation. Several studies suggest that long-term MPH may reduce depression and suicide in ADHD. Evidence suggests caution in specific groups including pre-school children, those with tics, and adolescents at risk for substance misuse. We identified a need for more studies that make use of large longitudinal databases, focus on specific neuropsychiatric outcomes, and compare outcomes from long-term MPH treatment with outcomes following shorter or no pharmacological intervention.en
dc.description.urihttps://www.sciencedirect.com/science/article/pii/S0149763419302350en
dc.formatFull text uploaded
dc.subjectAttention deficit disorder with hyperactivityen
dc.subjectSleep wake disordersen
dc.subjectSuicideen
dc.subjectSubstance-related disordersen
dc.subjectPsychosisen
dc.subjectAnxietyen
dc.subjectTicsen
dc.subjectSeizuresen
dc.subjectBipolar disorderen
dc.subjectDrug therapyen
dc.subjectArticle in pressen
dc.titleNeurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence [In Press]en
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record